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Abstract
Epoxide hydrolases (EHs) are enzymes that catalyze the ring opening of an epoxide, yielding a
vicinal diol. This exciting class of enzymes is often associated with natural product and small molecule
biosynthesis. One interesting class of natural products that epoxide hydrolases are involved in the
biosynthesis of is the enediynes. Previously, 5 enediyne-associated epoxide hydrolases have been
characterized, revealing an inverting-versus-retaining paradigm for enediyne epoxide hydrolases. The
work described herein sets the table for future studies involving the probing of the α/β-epoxide
hydrolase mechanism for styrene oxide. Kinetic and regioselectivity characterization of the enediyneassociated CynF and SghF has determined that SghF may be a robust starting platform for engineering
efforts in the hopes of generating enantiomerically pure diols through biocatalysis. SghF represents the
most efficient (Kcat/Km of 190 for (S)-styrene oxide) and enantioselective (E=655, in favour of the (S)epoxide) enediyne-associated epoxide hydrolase characterized to date. The identification of conserved
residues at positions Y138, L187, A188, D189, P190, E191, H192, A194, F229, Q303, L304, and Q370 may
represent critical sites for investigation in the hopes of generating a robust catalytic toolkit for the
production of enantiomerically pure diols from a wide variety of epoxide hydrolases and substrates.
Finally, regioselectivity characterization of CynF and SghF has confirmed that CynF is a retaining epoxide
hydrolase, and SghF is an inverting epoxide hydrolase, thereby expanding the inverting versus retaining
paradigm for enediyne epoxide hydrolases.
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Introduction
Epoxide Hydrolases
Epoxide hydrolases (EHs) are enzymes that catalyze the ring opening of epoxides, yielding a
corresponding diol. Putative EHs have been found in approximately 20% of all sequenced organisms 1,
and the majority of EHs that have sequence information available are contained within one of two
structural families: the limonene-1,2-epoxide hydrolase fold family, and the α/β hydrolase fold family2.
The majority of EHs are contained within the α/β hydrolase fold family2. Enzymes contained within this
family possess a main domain comprised of a single central β-sheet that is enclosed by several α-helices
and a variable cap domain positioned at the top of the substrate binding site 3. Epoxide ring opening by
α/β EH catalysis is achieved through a strongly conserved Asp/Ser/Cys-His-Asp/Glu catalytic triad,
located on the main domain which highly resembles other α/β-fold enzymes2. The substrate epoxide is
anchored by two conserved tyrosine residues located on the cap region of the enzyme 4. The
nucleophile for α/β hydrolase fold EHs is an invariable aspartate 1 which attacks at the least hindered
carbon of the epoxide ring, leading to the formation of an alkyl enzyme intermediate (Figure 1) 5. An
Asp-His-Asp triad then activates a water molecule that hydrolyzes the ester, releasing the product diol 6.
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Figure 1. Proposed catalytic mechanism for the hydrolysis of styrene oxide by an α/β-fold epoxide
hydrolase. The active site residues reflect the predicted active site residues in the AnEH from
Aspergillus niger
EHs are important for the biosynthesis of some microbial natural products that possess a wide
array of therapeutically relevant bioactivities, such as antimicrobial, antifungal, and antitumour
properties 7. While the scaffold of many of these clinically relevant secondary metabolites are
synthesized by type I polyketide synthases (PKSs) and non-ribosomal peptide synthases (NRPSs), EHs are
among several tailoring enzymes that are involved in the decoration of natural product scaffolds to yield
the mature molecule 8,9.
One of the important classes of microbial natural products are the enediynes. EHs are important
in the biosynthesis of enediynes that possess a 9-membered ring structure, or enedidyne core, which
acts as the “warhead” that induces breaks in double-stranded DNA 10. Enediynes have great potential as
antitumour antibiotics, with extreme potencies (IC50s as low as 10-3pM for selected cancer cell lines). The
biosynthesis of the enediyne core is poorly understood; however recent work has provided
understanding on how special peripheral moieties are added to 9-membered enediyne cores via a
vicinal diol handle 11. Interestingly, it appears as though the vicinal diol is generated as a result of the
hydrolysis of an (S)-epoxide by an EH 12. Furthermore, the resultant configuration of the stereocenter in
the mature enediyne is dictated by the regioselectivity in the associated EH (Figure 2). For instance,
enediynes possessing an (R)-vicinal diol are generated from the hydrolysis of the (S)-epoxide precursor
catalyzed by an EH that inverts the stereochemistry of the precursor by attacking at the more hindered
carbon 13. In contrast, (S)-vicinal diols are generated from the hydrolysis of the (S)-epoxide precursor by
attacking at the less hindered carbon. EHs that invert the stereochemistry of the epoxide precursor are
called “inverting” EHs, while EHs that retain the stereochemistry of the epoxide precursor are called
“retaining” EHs 13.
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Figure 2. Familial classification of currently characterized enediyne epoxide hydrolases. Adapted from 13.
To date, 5 enediyne-associated EHs have been characterized and reveal some unusual features
compared to canonical EHs. A sequence alignment of these enzymes reveals features typical of EHs: (i)
the catalytic triad residues D175, D336, and H363 (KedF numbering) and (ii) the two epoxide-binding
residues at positions Y236/W236 and Y304 13. Surprisingly, although all characterized EHs possess Tyr
residues that bind to the epoxide oxygen, the three known inverting EHs have had one of the canonical
tyrosine residues replaced with tryptophan at position 236. Previous phylogenetic analysis suggests that
there is a familial link for inverting versus retaining EHs 13.
Earlier research done by Horsman et al. on the inverting EH SgcF 13 has probed the molecular
determinants of EH catalysis through the mutation of the active-site tryptophan (W236) to the canonical
tyrosine. Indeed, the mutation did marginally increase the retaining activity of the enzyme; however,
only with an accompanying mutation in the neighboring residue (W236Y/Q237M) was there an
appreciable increase in the enzyme’s retaining activity towards styrene oxide 13. Despite this, there was
still significant inverting activity in the double mutant. Clearly, epoxide hydrolase regioselectivity is far
more complex than the diagnostic tyrosine to tryptophan mutation, and the molecular determinants of
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EH inverting versus retaining catalysis remain elusive. Comprehension of these molecular determinants
is vital to unlocking the potential for EHs to be used in biocatalysis.

Biocatalysis
Biocatalysis involves the application of both enzymes and microbes as catalysts in synthetic
chemistry 14. It may also include the use of natural catalysts for processes which have not yet naturally
evolved. First employed centuries ago, biocatalysis has grown in complexity from the use of plant and
microbial cell extracts to perform simple chemical transformations to the industrial preparation of high
value chirally pure synthetic intermediates for pharmaceuticals 15. The discovery of microbial epoxide
hydrolases has broadened the scope of EH research to include their application in biocatalysis1. EHs are
prime candidates for biocatalysis due to the wide range of substrates that they are capable of accepting,
ranging from small aliphatic to bulky polyaromatic epoxides2. Furthermore, microbial epoxide
hydrolases do not require expensive cofactors, prosthetic groups or metal ions for activity, making them
attractive for large-scale industrial applications16. Indeed, not only are microbial epoxide hydrolases easy
to produce in large quantities, but the cloning and overexpression of several enantioselective epoxide
hydrolases has facilitated their large-scale production and improvement of their biocatalytic capabilities
by either random or site-directed mutagenesis 1,6,16,17. Furthermore, powerful modeling tools and
algorithms have allowed researchers to engineer biocatalysts to perform in unnatural solvents,
increased temperature stability, and increased enantio- and regioselectivity 18–23. Additionally, The
establishment of new techniques for creating more efficient screening libraries such as triple codon
saturation mutagenesis (TCSM) and fast screening techniques such as on-chip analysis of enantiomeric
transformations continues to further the potential practicality and applicability of EHs in
biotransformations 23,24.
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Despite the alluring nature of the use of enzymes for biocatalytic transformations, there still
remain several drawbacks to enzyme catalysis that must be overcome before their widespread use in
industry is realized. A major drawback to the use of enzymes for industrial scale biotransformations is
often their instability to the conditions employed. Although researchers are able to engineer and
improve upon natural catalysts, the final engineered enzyme is frequently unsuitable for use in industrial
processes. The conditions employed are often significantly different when compared to the enzymes’
natural environment in the cell, including non-natural substrates, non-aqueous conditions, and extremes
of pH 25. A more robust understanding of EH catalysis and engineering will inform the design and
engineering of EHs that are capable of generating pure stereoisomers from a wide variety of substrates
in a predictable manner.
Regioselective EHs could be used as biocatalysts to generate enantiomerically pure (R)- or (S)-1,
which can be used as a chiral substrate in the production of high value synthetic intermediates such as
sulfamidates and bioactive compounds such as the kinase inhibitor BMS536924, the β-blocker (R)Nifenalol ®, and deacetylase inhibitor 21,26–28. Furthermore, it has been shown that EHs are not only
comparable in yield and efficiency to conventional catalysts, they can often exceed the capabilities of
conventional organic synthesis (Figure 3) 12,21. Moreover, dependence on heavy-metal based catalysts
presents an environmental risk.
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97% ee and > 80% yield
AD-mix is heavy metal based
$5.60/g of catalyst
$25/g for 2-bromostyrene
$8.50/g for 4-bromostyrene
99%ee and 87% yield
$1.10/g for each catalyst
$0.30/g for styrene oxide

Figure 3. (A) Enantiomerically pure 1-phenyl-1,2-ethanediol as a chiral substrate for high value
pharmaceuticals. (B) Comparison of a conventional catalyst against the combined action of the
EHs SgcF and NcsF2 13

Bioinformatics and Computational Tools for Annotating Enzyme Function

The amount of protein sequence data available has increased exponentially in the last decade;
the number of sequence entries in the UniProtKB database exceeds 65,000,000 as of early July 2016.
The bounty of protein sequences available is a boon for researchers, as the understanding of enzyme
functions and their associated metabolic pathways should allow for advances in not only industry, but in
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medicine, chemistry, and synthetic biology 29. However, the number of enzymes that have been
assigned reliable in vitro functions is greatly outnumbered by the genes that have only been assigned
putative function. These genes only share a marginal amount of sequence similarity to related enzymes,
making assumptions on their molecular function difficult. Furthermore, a large amount of functional
annotations assigned to genes are incorrect; as much as 40% of genes in public databases are
misannotated 30.
As such, there is an increasing need to determine reliable functions for biochemically
uncharacterized proteins. Given the number of unknown sequences, biochemical experimentation alone
is not a feasible strategy 29. Computational tools can be used to complement biochemical
experimentation and reliably annotate functions for proteins that cannot be characterized
experimentally. Bioinformatic analyses can assign tentative functions by grouping similar enzymes into
clusters with a single hypothesized function. Additionally, biochemical characterization of two enzymes
with opposing activities (i.e. inverting and retaining EHs) that are closely related allows for the in-depth
analysis of subtle differences in enzyme sequence, structure and function that leads to opposing
regioselectivity in EHs.
The CytoScape network generated through the Enzyme Function Initiative 29 shown in Figure 4
demonstrates the relationship of known EHs to each other in 2-dimensional space. Closer examination
of this network reveals that the EHs containing the tryptophan mutation that is diagnostic of inverting
catalysis are all closely related to one another. Furthermore, this cluster of putative inverting EHs is
surrounded by EHs which have both of the conventional epoxide-binding tyrosines, which are predicted
to be retaining EHs. Two highly related EHs have been selected for investigation. The EHs SghF (from
Streptomyces ghanaensis sp. ATCC-14672) and CynF (from Streptomyces sp. CNT-179) have been
selected because: i) they are highly related and found in gene clusters encoding for enediynes and ii)
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they are predicted, by the familial classification of enediyne epoxide hydrolases, to possess opposing
regioselectivities.

Figure 4. Full CytoScape cluster for epoxide hydrolases. Each node in the cluster is representative of a
protein sequence. A line connecting two nodes is indicative of relatedness. Inset clustering of
tryptophan epoxide hydrolases, and the genes selected for this study. Purple nodes represent
EH sequences which possess the canonical tyrosine residue at position, green nodes respresent
EHs which possess a phenylalanine residue, pink nodes represent EHs which possess a histidine
residue, and yellow nodes represent EH sequences that possess a tryptophan residue.

Objectives
Bioinformatic analysis has already identified two epoxide hydrolases, CynF and SghF, which are
highly similar, but are expected to exhibit opposing regioselectivities. Biochemical and structural
characterization of these enzymes will lead to a more robust understanding of EH catalysis and
selectivity. It is also important to be able to identify suitable EHs for the purposes of biocatalysis.
Therefore, the goals of this project were as follows:
(1) Perform a bioinformatics analysis on the known tryptophan EHs and compare them to similar
tyrosine EHs that are nearby in the SSN. This may lead to identification of the conserved
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catalytic residues within CynF and SghF. This may also lead to novel amino acid sites to further
investigate the molecular determinants of EH regio- and enantioselectivity.
(2) Biochemically characterize and solve the protein crystal structure of the EHs CynF and SghF.
Characteristics of these enzymes may be used to assign reliable activities to nearby enzymes
within the EH CytoScape network and further expand the inverting versus retaining paradigm of
enediyne epoxide hydrolases.
(3) Generate epoxide hydrolase mutants that are expected to alter or hinder the EH catalytic
mechanism. Structural characterization of these mutants would allow visualization and probing
of each step of EH catalysis.

Materials

Instrumentation

Agarose gel electrophoresis was performed using a Midi 10 Gel Electrophoresis system (VWR,
Radnor, PA). Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed
using a Mini PROTEAN Tetra Gel Electrophoresis chamber (Bio-Rad, Berkeley, CA). Power for
electrophoresis was provided by a 300V power source (VWR, Radnor, PA). Ultrapure water was obtained
using a Synthesis A10 Water Purification System (Milli-Q, Etobicoke, ON). Microcentrifugations at room
temperature were performed using a 5415C microcentrifuge (Eppendorf, Hamburg, Germany).
Centrifugations done at 4 oC were performed using a Heraeus Multifuge X1R (ThermoFisher Scientific,
Waltham, MA). High performance liquid chromatography was done using a Shimadzu Prominence HPLC
(Mandel, Guelph, ON). Reverse-phase HPLC was done using an Alltima C18 column ((5μm, 150mm x 4.6
mm), Alltech, Columbia, MD). Chiral HPLC was done using a Chiralcel OD-H column ((5µm, 4.6mm x
250mm) Diacel, Westchester, PA). Miscellaneous spectrophotometry (Bradford Assay and optical
density analysis) was performed using a Spectramax 384 Plus (Molecular Devices, Sunnyvale, CA).
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Shaking incubation of cell cultures was done using a MaxQ incubating shaker (ThermoFisher Scientific,
Waltham, MA). Incubation of LB agarose plates was done using a Heratherm Compact microbiological
incubator (ThermoFisher, Waltham, MA). Vortexing was done using a Thermolyne MaxiMix II vortexer
(ThermoFisher, Waltham, MA). Sonic disruption of cells was done using a Q125 sonic processor (QSonica, Newtown, CT). Ultrafiltration was done using a Macrosep Advance 30k MWCO Centrifugal
Device (Pall Corporation, Mississauga, ON). Buffer exchange and desalting was done using EconoPac
10DG columns (Bio-Rad, Berkeley, CA). Anion exchange was performed using a Hi-Trap Q FF 5mL Anion
Exchange column (GE Life Sciences, Mississauga, ON). Size exclusion chromatography was performed
using an Enrich SEC 350 24mL gel filtration column (Bio-Rad, Berkeley, CA). Fast protein liquid
chromatography was done using a NGC Quest Medium Pressure Chromatography system (Bio-Rad,
Berkeley, CA). Epoxide hydrolase kinetics was monitored spectrophotometrically using a Cary 60
UV/Visible spectrophotometer with an attached PCB1500 water peltier system (Agilent Technologies,
Santa Clara, CA) to maintain a constant temperature. Initial protein crystallography screens were
performed using a Gryphon crystallography robot (Art Robbins Instruments, Sunnyvale, CA), and
microscopy of potential crystallography hits was done using SZX16 microscope with an attached
Highlight 3100 light source (Olympus, Toyko, Japan).

Kits
Extraction of DNA from agarose gels and general DNA purification was performed using the
Wizard SV Gel Extraction and PCR Clean-Up kit (Promega, Madison, WI). SDS-PAGE gels were cast using
the TGX FastCast Stain-Free Acrylamide kit (Bio-Rad, Berkeley, CA). Plasmid DNA minipreps were done
using a PureYield Plasmid miniprep kit (Promega, Madison, WI). High fidelity PCR was done using the
Phusion DNA high-fidelity DNA polymerase (ThermoFisher Scientific (Waltham, MA). Adenine overhang
addition was done using EconoTaq polymerase (Lucigen, Middleton, WI). Cloning was done using the
pGEM-T-Easy vector system (Promega, Madison, WI). Initial crystal screening was done using Index and
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Crystal Screen 1 and 2 (Hampton Research, Aliso Viejo, CA) and MCSG-1, -2, -3, and -4 (Anatrace,
Maumee, OH).

Chemicals and Other Materials
The following is a list of chemicals and suppliers used in the methodology of this project:
pUC57-SghF (BioBasic, Markham, ON); pET28 (Geoff Horsman, Madison, WI); pET29 (Geoff Horsman,
Madison WI); Cosmid O19 containing the cynF gene (Amy Lane, Jacksonville, FL); Tryptone
(ThermoFisher, Waltham, MA); yeast extract (Amresco, Cleveland, OH); NaCl (Amresco, Cleveland, OH);
polyethyleneglycol 8000 (ThermoFisher Scientific, Waltham, MA); bacteriological agar (Alfa Aesar,
Haverhill, MA); Sterile DMSO (ThermoFisher Scientific, Waltham MA); non-sterile DMSO (BioBasic,
Markham, ON); MgCl2 • 6H2O (Amresco, Cleveland, OH); Agarose (Amresco, Cleveland, OH); Sucrose
(VWR, Radnor, PA); Bromophenol Blue (Amresco, Cleveland, OH); dNTPs (10mM each) (ThermoFisher
Scientific, Waltham, MA); 50mM MgCl2 (ThermoFisher Scientific, Waltham, MA); Ethanol (Commercial
Alcohols, Brampton, ON); Coommassie Blue G-250 (Amresco, Cleveland, OH); Phosphoric Acid
(Anachemia, Missisauga, ON); Restriction enzymes (ThermoFisher Scientific, Waltham, MA); Egg white
lysozyme (BioBasic, Markham, ON); IPTG (BioBasic, Markham, ON); His-Pur Ni-NTA slurry (ThermoFisher
Scientific, Waltham, MA); DNase I (Sigma Aldrich, St. Louis, MO); Ethidium bromide (Millipore,
Etobicoke, ON); Ampicillin sodium salt (VWR, Radnor, PA); Kanamycin sulfate (Amresco, Cleveland, OH);
X-GAL (TEKNOVA, Hollister, CA); NaOH (Amresco, Cleveland, OH); Racemic styrene oxide (Sigma Aldrich,
St. Louis, MO); Ethyl acetate (VWR, Radnor, PA); Acetonitrile, HPLC grade (ThermoFisher Scientific,
Waltham, PA); Isopropanol, HPLC grade (ThermoFisher Scientific, Waltham, PA); Hexane, HPLC Grade
(ThermoFisher Scientific, Waltham, PA); (R)-styrene oxide (Sigma Aldrich, St. Louis, MO); (S)-styrene
oxide (Sigma Aldrich, St. Louis, MO); racemic 1-phenyl-1,2-ethanediol (Sigma Aldrich, St. Louis, MO); (R)1-phenyl-1,2-ethanediol (Sigma Aldrich, St. Louis, MO); (S)-1-phenyl-1,2-ethanediol (Sigma Aldrich, St.
Louis, MO); Sodium periodate (Sigma Aldrich, St. Louis, MO); Bis-Tris (VWR, Radnor, PA); Sodium acetate
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(BioShop, Burlington, ON); Hydrochloric acid (VWR, Radnor, PA); Calcium chloride (Amresco, Cleveland,
OH); Ethylene glycol (BioShop, Burlington, ON); Tris (VWR, Radnor, PA); Imidazole (ThermoFisher
Scientific, Waltham, MA); Sodium phosphate monobasic (Amresco, Cleveland, OH); Sodium phosphate
dibasic (Amresco, Cleveland, OH); Polyethylene glycol 3.35k (Hampton Research, Aliso Viejo, CA);
Polyethylene glycol 8k (ThermoFisher Scientific); Polyethylene glycol 400 (Hampton Research, Aliso
Viejo, CA); Polyethylene glycol monomethyl ether (Hampton Research, Aliso Viejo, CA); Ammonium
Sulfate (VWR, Radnor, PA); Tetramethylethylenediamine (Amresco, Cleveland, OH); Carbenicillin sodium
salt (ThermoFisher Scientific, Waltham, MA); Ammonium persulfate (BioShop, Burlington, ON).

Methodology

All agarose gels were prepared by combining 1.0% (w/v) of agarose to the appropriate volume
of Tris-Acetate-EDTA (TAE, 0.04M Tris-Acetate, 0.001M ethylenediaminetetraacetic acid (EDTA)) buffer
and heating in a microwave until fully dissolved. The gel was then left to cool and ethidium bromide
(0.5µg/mL of gel) was added and poured into an appropriate plastic mold. A well-forming comb was
then inserted and the gel was left to solidify at room temperature. Once solidified, the gel was placed in
the gel tray and submerged in TAE buffer. All unstained DNA was diluted 1:1 with DNA staining solution
(0.25% bromophenol blue, 40% (w/v) sucrose) to aid in DNA sample addition into the gel wells. DNA
samples were then loaded into the wells using a micropipette and the cover was placed on the chamber.
The electrophoresis apparatus was then attached to a power source and run for 45 minutes at 100V.
The gel was then removed from the gel tray and placed onto a Bio-Rad Gel Doc Easy UV Tray for gel
imaging.

Bioinformatics Analysis
The CytoScape network generated was used to identify the cluster of EHs which possess the
tryptophan mutation. The 6 nearest EHs possessing the canonical tyrosine residue in the SSN were
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selected for analysis by sequence alignment and aligned with the 6 identified tryptophan-containing
EHs. The amino acid sequences of the selected genes were retrieved from the UniProt KB database 31
and used for sequence alignment by Clustal Omega 32,33.

Polymerase Chain Reaction
Polymerase Chain Reaction (PCR) was performed using a Bio-Rad C1000 Touch Thermal Cycler. A
100µL master mix was made by combining 55µL of nuclease-free water, 20µL 5X HF Phusion Green
Buffer, 10µL dimethyl sulfoxide (DMSO), 3µL deoxynucleotide phosphate (dNTP) mix, 2µL 50mM MgCl2,
3µL forward primer, 3µL reverse primer, 3µL forward primer, 3µL template DNA, and 1µL Phusion HiFi
polymerase. The master mix was then dispensed into 10uL aliquots for thermal cycling. Cycling
parameters are outlined in Table 1.
Table 1. Cycling parameters for PCR amplification
Step # Temperature (oC) Time (min:sec)
1

94

2:00

2

94

0:15

3

Gradient 50-65

0:10

4

72

1:10, return to step 2 x30

5

72

5:00

6

4

Infitinite hold

Preparation of Luria Broth and Luria Broth Agar for Escherichia coli Cultivation
Luria Broth (LB) was prepared by combining 10g/L tryptone, 5g/L yeast extract, and 10g/L NaCl
in ultrapure water from a Milli-Q Synthesis A10 Water Purification system from Millipore (Etobicoke,
ON). The prepared LB was then sterilized using the liquid sterilization program in a Steris Amsco Lab 250

20
steam sterilizer (Mississauga, ON). LB Agar was prepared by adding an additional 1g/L of agar to LB prior
to sterilization.

Preparation of Escherichia coli Competent Cells
A glycerol freezer stock of E.coli DH5α or BL21 was streaked onto Lysogeny broth (LB) agar and
allowed to grow overnight at 37 oC. A single colony was then picked and used to inoculate 50mL of LB
and allowed to grow at 37 oC with shaking until the optical density at 600nm (OD600) reached
approximately 0.5. The culture was transferred to 2 ice-cold sterile 50mL conical tubes and let to sit on
ice for 10 min. The cultures were then centrifuged at 4 oC for 10 min at 2700 x g. The supernatant was
then poured off and cells were resuspended in 10mL of ice cold sterile TSS buffer (2.0% (w/v) NaCl, 2.0%
(w/v) tryptone, 0.5% (w/v) yeast extract, 10% (w/v) polyethylene glycol 8000, 0.5% (v/v) dimethyl
sulfoxide, 1.0% (w/v) MgCl2 • 6H2O, pH 6.5), dispensed into 200µL aliquots and flash frozen using liquid
nitrogen. The competent cells were then stored in a Revco Elite upright freezer at -80 oC until needed.

Transformation of DNA into E. coli Competent Cells
Competent cells were allowed to thaw on ice, and approximately 30-80ng of DNA were pipetted
directly into the cells and allowed to sit on ice for 20-30 min. The cells were then heated at 42 oC for 2
min. After heating, 1mL of LB was added and the cultures were allowed to incubate at 37 oC for 1h with
agitation. The cultures were then spun down at full speed for 1 minute, and most of the supernatant
was discarded, while approximately 100μL of supernatant was reserved. The cell pellets were
resuspended in the reserved supernatant and plated onto LB agar containing 10µg/mL kanamycin for
pET29 constructs and 20µg/mL ampicillin, 80µg/mL X-Gal and 200µg/mL IPTG for pGEM constructs. The
plates were then incubated for at least 12 hours at 37 oC. Positive transformants for incorportation into
pET29 are indicated by growth, while positive transformants for pGEM are indicated by growth and the
absence of a blue colour change. Colonies were then picked into 3mL of LB containing the appropriate

21
antibiotic using a sterile inoculating loop and allowed to grow overnight at 37 oC with shaking. The
plasmid DNA is then purified through plasmid DNA miniprep. If required, a glycerol freezer stock is first
made using 20% sterile glycerol and adding cell culture with E.coli DH5α containing the construct to 1mL
and stored at -80 oC.

Preparation of DNA Primer Stocks
DNA primers were purchased as dry residue from Integrated DNA Technologies (IDT, Coralville,
IA). A 100µM stock was prepared by adding an appropriate amount of nuclease-free water and the DNA
was dissolved thoroughly by agitation with a vortexer. An additional 100µL of 10µM working stock was
then prepared by combining 10µL of 100µM stock with 90µL of sterile water. Unless otherwise noted,
the 10µM working stock was used for polymerase chain reactions.

Removal of Gycerol and Sodium Azide from Centrifugal Device Membranes
Centrifugal devices were rinsed by flow through of 10mL of ultrapure water by centrifugation for
10 minutes at 2,700 x g. Both the filtrate and the retentate were disposed. A second rinse with 0.05N
NaOH was performed by centrifugation for 10 minutes at 2,700 x g, and once again the filtrate and
retentate were disposed of. A final 10 minute rinse at 2,700 x g with ultrapure water was then done to
remove any residual NaOH. The columns are then stored in ultrapure water at room temperature until
needed.

Restriction Enzyme Digests
Restriction enzyme digests were performed using up to 1µg of DNA, 2µL of 10X FastDigest Green
Buffer, 1µL of an appropriate restriction enzyme (1µL of each enzyme for double digests). Nuclease-free
water was used to dilute the reaction to 20µL. The digests were allowed to incubate at 37 oC for 20
minutes before loading onto a 1% agarose gel for separation. Electrophoresis was performed as
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described in previous sections. Digests that were to be used downstream were extracted from the gel
after electrophoresis.

pGEM-T Easy Ligation
DNA was ligated into pGEM-T-Easy using the following mixture: 60ng of insert DNA, 20ng of
pGEM-T-Easy, 5µL of 2X Rapid Ligation Buffer, and 1µL of T4 DNA Ligase. Where required, nuclease-free
water was used to bring the total reaction volume to 10µL. A separate positive control was prepared by
replacing the insert DNA with 3µL of Control Insert DNA, and a negative control was prepared by
replacing the insert DNA with nuclease-free water. The reactions were incubated overnight at 4 oC, and
transformed into E. coli DH5α.

pET29 Ligation
DNA was ligated into pET29 using the following mixture: 20ng of pET29, 60ng of insert DNA, 1µL
of 10X T4 Ligase Buffer, and 1µL of T4 DNA ligase. A negative control was performed by replacing the
insert DNA with nuclease-free water. The reactions were incubated at 4 oC overnight, and transformed
into either E. coli DH5α for plasmid miniprep, or E. coli BL21 (DE3) for protein expression.

Cloning of the CynF and SghF genes that encode epoxide hydrolases

Cosmid AD12 containing the CynF gene from Streptomyces sp. CNT-179 was obtained from Amy
Lane, U. North Florida. The CynF gene was amplified using the polymerase chain reaction (PCR) with
primers CynF-NdeI-F and CynF-XhoI-R (Table 2). A master mix was made as previously described and
dispensed into 10μL aliquots for the annealing gradient. Cycling parameters used are summarized in
Table 1. The CynF PCR product has additional 3’ XhoI and 5’ NdeI sites, as well as a MAH6VD4K Nterminal tag to allow for production of a His6-tagged epoxide hydrolase product similar to previously
characterized SgcF produced from pBS1096 11. The PCR product was run on a 1% (w/v) agarose gel and
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amplicons corresponding to the correct size were extracted using the Wizard Gel Extraction and PCR
Cleanup kit. A single adenine-overhang was then added to assist in annealing to pGEM T-Easy as
previously described. The gel extract was then ligated into pGEM-T Easy as previously described to
produce the sequencing construct CynF-pGEM. The construct CynF-pGEM was then sent to the Centre
for Applied Genomics in Toronto, Ontario for sequencing via the T7 forward and SP6 reverse sequencing
primers. The retrieved sequence was then confirmed using the NCBI BLAST tool.
Table 2. Primers used for cloning procedures described. Restriction enzyme cut sites are underlined.
Fusion tags are bolded.

Primer Name

Sequence

CynF-NdeI-F

5’-CATATGGCACATCACCACCACCATCACGTGGATGACGACGACAAG
ATGGATCCCTTTCGGATCGACATC-3’

CynF-XhoI-R

5’-CTCGAGCTACCGGCCGGGCAGCGATCG-3’

The vector pUC57-SghF containing the SghF gene from S. ghanaensis sp. ATCC-14672 was
purchased from BioBasic (Markham, ON). The restriction sites for NdeI and XhoI present at the 5’ and 3’
end of the gene allow for the restriction enzyme digest and ligation of the SghF gene into the vector
pET28 from Geoff Horsman (Madison, WI). The above method was also used to clone the CynF gene
from the CynF-pGEM construct into the vector pET29 from Geoff Horsman (Madison, WI).

Preparation of EH Mutants by Overlap Extension PCR

PCR primers that flank the gene of interest were ordered from Integrated DNA Technologies
(Coralville, IA) that contain a mismatched amino acid codon at an appropriate location to yield a desired
mutant (Table 3). PCR primers matching the 5’ end and 3’ end of the SghF gene were also ordered from
Integrated DNA Technologies. Overlap extension PCR was performed in two rounds: the first round

24
includes the separate PCR amplification of the sections of the genes upstream and downstream of the
mutation. The CynF mutant with histidine 363 mutated to adenine (CynF-H363A) was prepared using
two separate PCR reactions, utilizing CynF-pGEM as a template. The first reaction was performed using
the primers CynF-NdeI-TAG-F and CynF-H363A-R to amplify the CynF gene upstream of the desired
mutation. The downstream portion of the gene was then prepared using the primers CynF-H363A-F and
CynF-XhoI-R and CynF-pGEM as the template sequence. After extraction via the Wizard Gel Extraction
and PCR Cleanup Kit from Promega, Fragments A and B were then spliced together via PCR using both
fragments as the template sequence, and the primers CynF-NdeI-TAG-F and CynF-XhoI-R. This final full
length CynF mutant CynF-H363A was then ligated into pGEM-T-Easy (Promega) after addition of the
adenine overhang using the techniques previously described.
Table 3. Primers used for the generation of EH mutants by overlap extension. Restriction enzyme cut
sites are underlined. Fusion tags are bolded.
Primer Name

Sequence

CynF-NdeI-TAG-F

5’-CATATGGCACATCACCACCACCAT -3’

CynF-XhoI-R

5’-CTCGAGCTACCGGCCGGGCAGCGATCG-3’

CynF-H363A-F

5’-CGCGAGGCGGCGCGTTCGCGGCC-3’

CynF-H363A-R

5’-GGCCGCGAACGCGCCGCCTCGCG-3’

CynF-H363Q-F

5’-CGCGAGGCGGCCAGTTCGCGGCC–3’

CynF-H363Q-R

5’-GGCCGCGAACTGGCCGCCTCGCG–3’

CynF-D175N-F

5’-CGCGGGCGGGAACTGGGGATC–3’

CynF-D175N-R

5’-GATCCCCAGTTCCCGCCCGCG-3’

SghF-Nat-F

5’-CATATGCGTCCTTTCCGCATCGAGATC-3’

SghF-H364A-F

5’-CAAGGGTGGTGCGTTCGCCGCGATG–3’

SghF-H364A-R

5’-CATCGCGGCGAACGCACCACCCTTG–3’

SghF-H364Q-F

5’-CAAGGGTGGTCAGTTCGCCGCGATG–3’
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SghF-H364Q-R

5’-CATCGCGGCGAACTGACCACCCTTG–3’

SghF-D176N-F

5’-CAGGGTGGAAACTGGGGTATGGCC-3’

SghF-D176N-R

5’-GGCCATACCCCAGTTTCCACCCTG-3’

The above method was used to generate the EH mutant constructs CynF H363A, CynF H363Q,
CynF D175N, SghF H364A, SghF H364Q, and SghF D176N. The pGEM-T-Easy ligated mutant epoxide
hydrolase constructs were then sent for sequencing at The Center for Applied Genomics, and sequence
verification as well as confirmation of successful mutation was done using the NCBI BLAST tool. The SghF
and CynF mutants were then subcloned into pET28 and pET29, respectively using the methods described
above for protein overexpression and purification.

Overexpression and Purification of EHs
Transformation of the expression constructs pET28-SghF and pET29-CynF into E. coli BL21 and
overproduction and purification of the resultant EHs were performed as previously established and
described above. A single transformant was picked and used to inoculate 50mL of LB containing
10µg/mL kanamycin and allowed to grow overnight at 37 oC with agitation. 4L of LB with 10µg/mL of
kanamycin was inoculated with the overnight growth, using a 1/100 dilution of cells and the culture was
incubated at 37 oC with agitation until it reached an OD600 of ~0.3, at which time the culture was
incubated at 18oC to an OD600 of ~0.5. At this point, 1mL was removed, centrifuged, the supernatant
discarded, and the pellet was frozen for later analysis of protein expression in whole cells prior to
induction. Overexpression of the protein was induced by addition of ITPG to the cell culture to a final
concentration 0.1 mM. The cell culture was then left to incubate overnight (at least 8 hours) at 18 oC
with agitation.
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Following incubation, a sample of the overnight cell culture was then diluted with LB to an OD600
of approximately ~0.5, centrifuged, the supernatant discarded, and the pellet was frozen for later
analysis. The remainder of the cell culture was then centrifuged at 4 oC for 10 minutes at 2,700 x g and
the supernatant discarded. The cell pellets were resuspended in sodium-phosphate buffer (I = 50mM),
0.3M NaCl, pH 7.5. Approximately 6% of the original culture volume will be used for resuspension (e.g
30mL of buffer for 500mL original cell culture). Approximately 2mg each of egg white lysosyme and
Bovine DNaseI were then added to the cell resuspension, and the resuspension was allowed to incubate
on ice for 30 minutes. The resuspension was then sonicated on ice with 6 x 10s pulses and 50s
intervening cooling periods at 40% amplitude, for a total of 60s of sonication. After the sonication step,
the lysed cells were transferred into high-speed centrifuge tubes and spun at 28,000 x g for 25 minutes
at 4 oC. The supernatant (raw extract, about 50mL) was transferred to a sterile, cold 50mL conical tube,
and 100µL was removed for later analysis. A portion of the pellet was also taken for analysis of insoluble
cell debris.
Exactly 2mL of Ni-NTA slurry per 500mL of original culture was added to the remaining raw
extract. The raw extract was then allowed to shake gently on ice for 10 minutes. The slurry mixture was
loaded onto a drip column and the flow through was collected and stored at 4 oC for further analysis.
The resin was rinsed twice with 5mL of wash buffer (50mM sodium phosphate, 0.3M NaCl, 20mM
imidazole, pH 7.4). Wash fractions were collected in 15mL conical tubes and stored at 4 oC for later
analysis. His-tagged proteins were eluted with elution buffer (50mM sodium phosphate, 0.3M NaCl,
250mM imidazole, pH 7.4). Elution fractions were pooled into a pre-rinsed 30kDa MWCO ultrafiltration
tube and concentrated by centrifugation at 4,000 x g for 40 minutes at 4 oC. The retained liquid was then
desalted using a desalting column using 20mM Tris-Cl, pH 7.5 as equilibration buffer. The eluate from
the column was then run over an anion exchange column attached to a Fast Protein Liquid
Chromatography (FPLC) system. FPLC equilibration was done using 20mM Tris-Cl, pH 7.5 (buffer A) and

27
gradient elution was done using 0-50% 20mM Tris-Cl, 1.0M NaCl, pH 7.5 (buffer B) over three column
volumes. A wash at 100% 20mM Tris-Cl 1.0M NaCl , pH 7.5 was then performed over two column
volumes, followed by a re-equilibration using 20mM Tris-Cl, pH 7.5 over two column volumes. Fractions
containing the desired protein were then concentrated using pre-rinsed 30k MWCO centrifugal devices
to 250µL for size exclusion. Size exclusion was performed using isocratic flow at 95% buffer A, 5% buffer
B over a single column volume. Fractions containing the desired protein were pooled and concentrated
in a 30k MWCO centrifugal device for 40 minutes at 4,000 x g. Following concentration, the protein
content of the sample was then quantified using the Bradford Assay.

Quantification of Protein by the Bradford Assay
Bradford Reagent was first prepared using 0.01% (w/v) Coomassie Blue G-250, 5% (v/v) ethanol,
10% (v/v) phosphoric acid diluted to an appropriate volume using ultrapure water. A standard curve was
then prepared using 0, 10, 20, 30 and 40µg of bovine serum albumin (BSA) in ultrapure water. 5mL of
Bradford Reagent was added to each standard sample and allowed to incubate for 6 minutes at room
temperature. The samples were then analyzed spectrophotometrically at 595nm, and a standard curve
was constructed through linear regression on Microsoft Excel. Using the standard curve, the protein
concentration in each sample was solved. Any samples whose absorbance was outside of the dynamic
range of the standard curve was diluted or re-made at a higher concentration and reanalyzed, as
required.

SDS-PAGE
Sodium dodecyl sulfate polyacrylamide gels were prepared using a TGX FastCast Stain-Free
acrylamide kit using the included instructions. Samples were prepared to include approximately 4μg of
protein in each well, to aid in protein purity analysis. Sterile H2O was used to dilute samples to 16μL as
required. Samples were prepared by adding 4μL of Laemmli reducing buffer (25mM Tris, pH 6.8, 20%
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(w/v) glycerol, 4% (w/v) sodium dodecyl sulfate, 10mM dithiothreitol, 0.015% (w/v) bromophenol blue)
to reach a total sample volume of 20µL and heated in boiling water for 5 minutes and allowed to cool at
room temperature. Once cool, the samples were spun in an Eppendorf 5415C microcentrifuge at 14,000
RPM for 1 minute to remove particulates. After loading the samples into the wells, the gel was run at
100V for 25 minutes to allow the samples to stack appropriately before entering the resolving gel. The
voltage was then turned up to 200V and the gel was run until the sample dye exited the bottom of the
gel. The gel was then removed from the apparatus and placed onto a Bio-Rad Gel Doc EZ Stain-Free tray
for gel imaging.

EH Activity Assays Towards Styrene Oxide
HPLC assays were performed as 200μL reactions containing 2mM racemic styrene oxide and
50mM sodium phosphate buffer, pH 8.0, as previously established 11. The reaction was initiated by
adding 50µM of enzyme and incubated at 25 oC for 1h. Control reactions which lack enzyme were
performed in parallel. After incubation, the reaction was halted by addition of 200µL of ethyl acetate
and agitated by vortexing. The reaction was then spun in a microcentrifuge at 14,000rpm for 1 minute to
allow for partitioning of the organic and aqueous portion of the reaction. The organic portion was
removed via micropippete and transferred to another 1.5mL microcentrifuge tube. The ethyl acetate
extraction was repeated two more times, for a total of 600µL of ethyl acetate. The extracted reactions
were left to air-dry overnight. The resulting residue was resuspended in 50µL of acetonitrile and
analyzed in 10µL injections by HPLC with PDA detection at 254nm. Using a flow rate of 0.25mL/min, a
25% acetonitrile in water elution was for 7 minutes, followed by 3 minutes in 100% acetonitrile. The run
ended with a 5 minute regeneration of the column at 25% acetonitrile in water.

Determination of EH Regioselectivity by Chiral HPLC
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Similar to the EH activity assays, chiral HPLC assays was performed as 200μL reactions
containing 2mM of either (S) or (R)-Styrene oxide and 50mM sodium phosphate buffer, pH 8.0. The
reaction was initiated by adding 50µM of enzyme and incubated at 25oC for 1h. Control reactions which
lack enzyme were performed in parallel. Additional controls were prepared by addition of (R) or (S)-1phenyl-1,2-ethanediol to allow for analysis of product retention times. After incubation, the reaction
was halted by addition of 200µL of ethyl acetate and agitated by vortexing. The reaction was then spun
in a microcentrifuge at 14,000rpm for 1 minute to allow for partitioning of the organic and aqueous
portion of the reaction. The organic portion was removed via micropippete and transferred to another
1.5mL microcentrifuge tube. The ethyl acetate extraction was repeated two more times, for a total of
600µL of ethyl acetate. The resulting residue was resuspended in 50µL of isopropanol and analyzed by
chiral HPLC in 10µL injections with PDA detection at 254nm. Chiral HPLC analysis was performed using
isocratic flow of 2.5% isopropanol in hexane for 90 minutes at 0.25mL/min. The obtained peak was then
compared to the product standards to determine the extent of enantioselectivity for each EH.
Co-injection was performed by addition of 1uL of 200mM of either (R) or (S)-1-phenyl-1,2ethanediol in isopropanol to the resuspended residue to confirm the identity of the retrieved product.

Determination of EH Enantioselectivity by Kinetic Assay
EH Kinetics were performed at 25 oC in a 1mL quartz cuvette. Reactions are performed with
10µL of 300mM NaIO4 in H2O, 25µL of 1-300mM (R) or (S)-styrene oxide in DMSO, and an appropriate
amount of enzyme in 50mM NaPO4, pH 8.0 to a total volume of 1mL

11

. Product diol formation by the

EH is followed by the rapid oxidation of the diol to benzaldehyde by NaIO4. Product formation is
monitored for several minutes by the increase in absorbance at 290nm. Michaelis-Menten kinetics were
fit to the data by comparing substrate concentration versus initial reaction velocity with the appropriate
regression tools in R, available online at https://www.r-project.org/.
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EH X-Ray Crystallography Trials
Purified native and mutant EHs were subjected to protein crystallography trials. 96-well screens
were performed as sitting drops in Intelliplate 96-well plates using a crystallography robot. All crystal
trays were incubated at 18 oC and checked every 72h using a microscope. Hits found in initial screens
were pursued as 24-well hanging-drop screens with slight variations to the initial hit. Diffraction of
protein crystals was initially monitored at the University of Waterloo (Waterloo, ON), and crystals found
to diffract sufficiently were sent to the Canadian Light Source (CLS, Saskatoon, SK). Molecular
replacement and iterative rounds of structure refinement were performed using Phenix34 and Coot35.

Results

Bioinformatics analysis

Alignment of the EH sequences from the cluster of tryptophan-containing EHs reveals several amino acid
sites which are conserved throughout the cluster (Figure 5). First, it is of note that the predicted protein
M0B613 from Natrialba asiatica is significantly divergent from the other tryptophan-containing EHs,
with large gaps appearing in the Clustal Omega-guided sequence alignment, despite showing the
catalytic triad and epoxide binding residues at the expected positions. Furthermore, the predicted
protein from N. asiatica is significantly shorter than the other tryptophan-containing EHs, which is
unsurprising, as N. asiatica is an archaeal protein. These characteristics of this predicted protein make it
difficult to compare to the other enzymes found in this cluster. Close analysis of the remaining EHs
within this cluster reveals several interesting residues which are only conserved in tryptophanconatining EHs. When mapped onto the solved crystal structure of SghF, several amino acid sites such as
A194, Q303, and Q370 (SghF numbering) appear to be distal from the active site of EHs (Figure 5). Of
these residues, Q303 merits further investigation, as this position is also conserved as either a histidine
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or an arginine in tryptophan-containing EHs. The mutation from a basic amino acid to a polar uncharged
amino acid may affect the cataytic cycle. Interestingly, a strongly conserved stretch of residues L187,
A188, D189, P190, E191, and H192 (Figure 5) present in tryptophan-containing EHs distal from the active
sites residues as well. Despite their distance from the active site, these residues are compelling
candidates for future engineering efforts in order to fine tune these EHs, as it has been found in many
cases that amino acids that are distal from the active site can affect catalysis. The residues Y138, F229,
and L304 are also conserved and are found proximal to the active site. Y138 is found quite close to the
epoxide-binding tyrosine-tryptophan pair, and is mostly conserved as a phenylalanine in tyrosinecontaining EHs. The phenylalanine in postion 229 is found beside the epoxide binding tryptophan, and is
mostly variable in tyrosine containing EHs. Finally, L304 is found immediately beside the invariable
epoxide-binding tyrosine, and once again is mostly variable in predicted retaining EHs. Altogether, the
conserved residues found within the sequence alignment merit further investigation, as these amino
acids which are conserved in the inverting EHs may hold the key to uncovering the molecular
determinants of the regioselectivity of epoxide hydrolases.
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Figure 5. Cartoon representation of the conserved residues within the tryptophan-containing EHs
shown on SghF. Conserved residues are shown in white.
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Figure 6. Alignment of tryptophan-containing EHs by Clustal Omega. Conserved residues are indicated
with asterisks. Oxyanion hole residues W100 and W177 are highlighted in yellow. Catalytic triad
residues D176, D337, and H364 are highlighted in red. Epoxide-binding residues W236 and Y304
are highlighted in blue (SghF numbering).
Similarly, alignment of the EH sequence that surround the tryptophan-containing EHs reveal
several other amino acid sites which are conserved throughout (Figure 6). First, the Acid/His/Acid
catalytic triad found in all α/β-fold epoxide hydrolases was confirmed to be present, at D176, H364, and
D336 (SghF numbering). Finally, the epoxide-binding residues were found at W236, and Y305. Similarly,
the tyrosine-containing EHs found proximal to the tryptophan-containing cluster were aligned, and the
Acid/His/Acid catalytic triad was found at D175, H363, and D335, and the epoxide-binding residues were
found at Y235 and Y304 (CynF numbering).
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Figure 7. Alignment of tyrosine-containing EHs by Clustal Omega. Conserved residues are indicated by
asterisks. Oxyanion hole residues W99 and W176 are highlighted in yellow. Catalytic triad
residues D175, D336, and H363 are highlighted in red. Epoxide-binding residues W235 and Y303
are highlighted in blue (CynF numbering).

Amplification and Cloning of the Genes that Encode SghF and CynF
The CynF gene was amplified as described using the primers CynF-NdeI-F and CynF-XhoI-R from
cosmid GD12, obtained from Amy Lane, University of North Florida. PCR products were run on a 1%
agarose gel. Amplicons of the expected size of ~1.2kb corresponding to the gene encoding CynF were
observed throughout the annealing gradient (Figure 7). The highlighted amplicon was extracted from
the gel and used for ligation into pGEM-T-Easy after addition of the adenine overhang.
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Figure 8. Image of PCR amplification of the genes encoding for cynF run on a 1% (w/v) agarose gel.
Annealing gradients of 50-65 oC were used and are loaded in ascending order left to right. 2µL
of Axygen 100bp DNA ladder is loaded in lane 1. The highlighted amplicon was extracted and
used for ligation into pGEM-T Easy.
The resultant DNA prep was digested with EcoRI and run on a 1% (w/v) agarose gel (Figure 8) to
verify the size of the insert. Plasmid DNA corresponding to the highlighted insert was confirmed by DNA
sequencing, yielding the construct cynF-pGEM-T Easy, with an encoded 5’ NdeI restriction site upstream
of the N-terminal MAH6VD4K fusion tag used in previous EH studies 13 and a 3’ XhoI restriction site to
allow for easy cloning into pET29.

Figure 9. Image of EcoRI digests of cynF-pGEM-T Easy run on a 1% (w/v) agarose gel. 2µL of Invitrogen
1kb+ ladder is loaded in lanes 1 and 10. Plasmid DNA corresponding to the highlighted inserts
were sent to The Center for Applied Genomics for sequence confirmation.
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The confirmed CynF-pGEM-T Easy construct was then subcloned into pET29, yielding the
expression construct CynF-pET29, encoding the CynF gene with an N-terminal MAH6VD4K fusion tag to
allow for both Ni-NTA affinity purification as well as cleavage of the tag by enterokinase.
The SghF gene was received as a synthesized pUC57 construct from BioBasic (Markham, ON)
with restriction enzyme sites for NdeI and XhoI at the 5’ and 3’ end of the gene respectively. Both the
SghF-pUC57 construct as well as an empty pET28 construct were digested with NdeI and XhoI to
produce the necessary sticky ends to allow for ligation (Figure 9). This yielded the expression construct
SghF-pET28, encoding the SghF gene with an N-terminal His6 tag upstream of a thrombin cleavage site,
allowing for Ni-NTA affinity purification as well as cleavage of the tag by thrombin.

A

B
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Figure 10. Agarose gel image of (A) SghF-pUC57 digested with NdeI and XhoI and (B) pET28 vector
digested with NdeI and XhoI. Highlighted bands were excised from the gel for ligation.

Generation of the EH mutants mutants SghF-H364Q, SghF-H364A, SghF-D176N, CynF-H363Q,
CynF-H363A, and CynF-D176N through overlap extension PCR
Primers were designed based on the catalytic residues of CynF and SghF in order to perturb the
native mechanism of the EHs. Mutants for CynF were prepared as previously described using overlap
extension PCR. The expression construct CynF-pET29 as the template for the initial round of PCR, along
with the appropriate pair of primers to yield the desired mutant. Once both the upstream and
downstream fragments of the gene were prepared, a second round of PCR was performed using the 5’
and 3’ primers. The mature PCR product was then run on a 1% (w/v) agarose gel to verify the size of the
amplicon. Once verified, the amplicon was excised from the gel and ligated into pET29 for protein
expression. Mutants for SghF were prepared in an identical manner; SghF-pET28 was used as the
template for the initial round of PCR (Figure 10 (A)), and the final verified amplicon was excised from the
gel and ligated into pET28 for protein expression (Figure 10 (B)). The constructs SghF-H364A-pET28,
SghF-H364Q-pET28, SghF-D176N-pET28, CynF-H363A-pET29, CynF-H363Q-pET29, and CynF-D175NpET29 were sent for DNA sequencing to confirm both the identity of the insert and the incorporation of
the mutation.
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A

B

Figure 11. (A) PCR amplification of SghF-D176N. The portions of the gene upstream (lanes 1-8) and
downstream (lanes 10-16) of the mutation are shown. Homologous amplicons were pooled
together for excision from the gel to improve DNA yield. 2µL of Invitrogen 1kb+ ladder were
used in lane 9 (B) Full extension amplification of the mutant SghF-D176N (lanes 1-8).
Homologous amplicons were pooled together for excision from the gel to improve DNA yield.
2µL of Invitrogen 1kb+ ladder were used in lane 9.

Expression and Purification of the EHs SghF and CynF, and the mutants SghF-H364Q, SghFH364A, SghF-D176N, CynF-H363Q, CynF-H363A, and CynF-D176N
After transformation of the appropriate expression construct into E.coli BL21, SghF (13.5mg/L),
SghF-H364Q (2.5mg/L), SghF-H364A (0.23mg/L), SghF-D176N (11.8mg/L), CynF (20.3mg/L), CynF-H363Q
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(3.2mg/L), CynF-H363A (0.1mg/L) and CynF-D175N (0.6mg/L) were purified to near homogeneity as Nterminal His6-tagged proteins by Ni-NTA affinity column chromatography, anion exchange
chromatography, and gel filtration chromatography as necessary. SDS-PAGE showed a single protein
band consistent with the expected molecular weight of all of the EHs purified (~45kDa).

HPLC Activity Assay for SghF and CynF and their Mutants
Due to unavailability of the natural substrates for CynF and SghF, styrene oxide was used as a
substrate analogue to test their activity. A single peak with a retention time identical to that of authentic
1-phenyl-1,2-ethanediol was observed in both cases (Figure 11 and Figure A6 in the Appendix).

A

B

Figure 12. HPLC activity assay for hydrolysis of racemic styrene oxide by (A) CynF and (B) SghF. (I) 1phenyl-1,2-ethanediol standard (II) control with no enzyme (III) styrene oxide treated with
50µM CynF
The reverse-phase HPLC assay performed was done in order to determine whether the purified
EHs were active towards styrene oxide. Close analysis of Figure 11 and Figure A6 in the Appendix reveals
that the HPLC profile for styrene oxide treated with either SghF or CynF provides a similar retention time
to that observed for authentic 1-phenyl-1,2-ethanediol. Although it is expected to exhibit absorbance at
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254nm and therefore provide an observable peak, there was not a significant peak that can be
attributed to styrene oxide in any of the control reactions. The absence of a peak can be attributed to
the evaporation of styrene oxide under low pressure conditions.

Enantioselectivity of CynF and SghF
Enantiomerically pure (R)- and (S)- styrene oxide were used to analyze the enantioselectivity of CynF and
SghF using chiral HPLC. Authentic (R)- and (S)- 1-phenyl-1,2-ethanediol were used to determine the
retention times for each product enantiomer (Figure 12). As the retention times for the authentic
standards differed from the eznyme-prepared products, co-injections were performed as described in
the Methods section. As expected, it was found that hydrolysis of (S)-styrene oxide by CynF resulted in
the retention of the stereocenter in the diol product, yielding (S)-1-phenyl-1,2-ethanediol (pane IV in
Figure 12). In addition, it was determined that hydrolysis of (S)-styrene oxide by SghF resulted in the
inversion of the stereocenter in the diol product, yielding (R)-1-phenyl-1,2-ethanediol (pane I in Figure
12). The retention times of the authentic (R)- or (S)-1-phenyl-1,2-ethanediol were significantly different
when compared to those for the enzyme hydrolysis product run on the same Chiralcel OD-H column. As
such, it was deemed necessary to perform a co-injection of the enzyme-catalyzed preparations with the
expected authentic diol. After co-injection, it was found that CynF-catalyzed hydrolysis of (S)-styrene
oxide yielded (S)-1-phenyl-1,2-ethanediol (pane V in Figure 12), and SghF-catalyzed hydrolysis of (S)styrene oxide yielded (R)-1-phenyl-1,2-ethanediol. CynF-catalyzed hydrolysis of (R)-styrene oxide
provided a mix of approximately two parts (R)- and one part (S)-1-phenyl-1,2-ethanediol, which is
consistent with results found for other EHs when hydrolysing (R)-styrene oxide 11. Interestingly, SghFcatalyzed hydrolysis of (R)-styrene oxide yielded little to no product diol, suggesting that the kinetics for
SghF-catalyzed hydrolysis of styrene oxide may strongly favour the (S)-enantiomer.
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Figure 13. HPLC assay for determining the stereochemistry of 1-phenyl-1,2-ethanediol as a result of
catalysis by CynF or SghF (I) SghF-catalyzed hydrolysis of (S)-styrene oxide, (II) SghF-catalyzed
hydrolysis of (S)-styrene oxide co-injected with authentic (R)-1-phenyl-1,2-ethanediol (III) SghFcatalyzed hydrolysis of (R)-styrene oxide, (IV) CynF-catalyzed hydrolysis of (S)-styrene oxide, (V)
CynF-catalyzed hydrolysis of (S)-styrene oxide co-injected with authentic (S)-1-phenyl-1,2ethanediol, (VI) CynF-catalyzed hydrolysis of (R)-styrene oxide, (VII) (R)-1-phenyl-1,2-ethanediol
standard, (VIII) (S)-1-phenyl-1,2-ethanediol standard.
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Kinetics of CynF and SghF and their mutants towards (R)- and (S)- styrene oxide
Michaelis-Menten kinetics parameters were determined (Table 4) for the native enzymes CynF
and SghF using a previously established assay 11,36. The activity of the mutants SghF-H364Q, SghF-H364A,
SghF-D176N, CynF-H363A, CynF-H363Q, and CynF-D175N were also analyzed through this assay.
Table 4. Steady-state kinetic parameters for CynF and SghF and variants and previously characterized
endiyne-associated EHs towards (R)- and (S)- styrene Oxide as substrates.
(R)-Styrene Oxide substrate
Kcat(min-1)
Km (mM)
Kcat/Km
ND
ND
0.29±0.045

EH
SghF
wild-type
SghFND
H364A
SghFND
H364Q
SghFND
D176N
CynF
ND
wild-type
CynFND
H363A
CynFND
H363Q
CynFND
D176N
SgcFa
7.5±0.7
a
SpoF
3.4±0.4
SgrFa
7.9±0.6
NcsF2b
133±4
c
KedF
35±2.4
ND= Not determined

ND

ND

(S)-Styrene Oxide substrate
Kcat(min-1)
Km (mM)
Kcat/Km
70.3 ± 1.7
0.37 ±
190
-1
min
0.036
ND
ND
ND

ND

ND

ND

ND

ND

ND

0.074±0.014 ND

ND

0.14±0.056 1.89

ND

0.11±0.013

ND

ND

0.61±0.16

5.55

ND

ND

ND

ND

ND

-

ND

ND

ND

ND

ND

-

ND

ND

ND

ND

ND

-

2.7±1.1
2.8±0.9
2.6 ±0.6
0.5±0.1
3.5±0.64

2.68
1.25
3.11
266
10.0

43±4
34±3
43±4
31±2
36.6±1.1

0.88±0.45
1.1±0.6
0.88±0.45
5.0±0.6
0.91±0.1

53.9
32.3
48.9
6.0
40.2

20.1
25.8
15.7
-44
4.0

E
655
-

E refers to the enantioselectivity [Kcat/Km(fast)]/[Kcat/Km(slow)] where for positive values (S)-styrene
oxide is the preferred (fast) substrate and for negative values (R)-styrene oxide is the preferred
substrate.
a

Values obtained from reference. 13

b

Values obtained from reference. 12

c

Values obtained from reference. 37

44
Interestingly, kinetic characterization of CynF reveals that is able to hydrolyze both the (S)- and
(R)- epoxide, with an apparent Kcat/Km of 0.61±0.16 and 0.11±0.013, respectively. CynF has an increased
catalytic efficiency for the (S)-styrene oxide (E=5.55, in favour of the (S)-epoxide), which agrees with the
hypothesis that the (S)-epoxide is the natural and therefore the favoured substrate for enediyneassociated epoxide hydrolases. Kinetic characterization of SghF reveals that it efficiently hydrolyzes the
substrate analogue (S)-styrene oxide, with an apparent Km of 0.37 ± 0.036 mM and Kcat of 70.3 ± 1.7 min1

, yielding a Kcat/Km of 190. SghF therefore represents the most efficient of the now 7 characterized

enediyne-related epoxide hydrolase for (S)-styrene oxide hydrolysis13. Interestingly, SghF can also
hydrolyze (R)-styrene oxide, with an apparent Kcat/Km of 0.29±0.045 (Table 4). This reduced catalytic
efficiency for the (R)-epoxide once again coincides with the hypothesis that the (S)-epoxide is the natural
substrate for enediyne-associcated epoxide hydrolases 11. SghF strongly prefers hydrolysis of the (S)epoxide, with an E-value of 655 in favour of the (S)-epoxide.

Structural Characterization of SghF and CynF and their Mutants
SghF protein crystals were obtained by vapor diffusion against 500µL of reservoir solution in a
3µL hanging drop at 18oC. The SghF protein was prepared in 50mM Tris buffer at pH 8.0 for initial crystal
screening, and drops were prepared by mixing the reservoir solution with SghF in either a 2:1 or 1:2
ratio. After harvesting, crystals were soaked in one of two cryprotectant solutions: 25% (w/v) glycerol,
20% (w/v) poly(ethylene) glycol 3.35k, 0.1M Bis-Tris, pH 6.5, or 27.5% (w/v) glycerol, 20% (w/v)
poly(ethylene) glycol 3.35k, 0.1M Bis-Tris, pH 6.5. The crystals were then flash frozen by rapid
submersion into a liquid nitrogen bath. Diffraction data were collected at the Canadian Light source and
refined to 2.7Å using the Coot and Phenix software packages (Figure 12).
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Figure 14. Cartoon representation of the solved crystal structure for SghF.
CynF and the mutants CynF-H363A, CynF-H363Q, and CynF-D175N were all subjected to 96-well
crystal screening as described in the Methodology section. Despite a large number of crystal screens
employed, there were no hits to follow up for any of CynF or its mutants.

Discussion
Two closely related epoxide hydrolases, CynF and SghF, were selected for bioinformatics
analysis and biochemical characterization. It was expected that characterization of these enzymes may
allow for the determination of the molecular determinants of epoxide hydrolase regio- and
enantioselectivity. Although these enzymes are highly related, they were expected to exhibit opposing
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regioselectivities as expected from the predictive model for enediyne epoxide hydrolase regio- and
enantioselectivity, first proposed by Horsman et al. 13.
Once the catalytic triad residues were determined for both CynF and SghF, it was decided that
several mutants were to be made. Previous work had suggested that the tyrosine to tryptophan
mutation found in inverting enediyne EHs was not involved in the retention or inversion of the
stereocenter in the diol product 13. As such, it was thought that generation would provide a platform
which would allow for the probing of the epoxide hydrolase catalytic mechanism.
As previously discussed, the catalytic mechanism proceeds in what is essentially two steps:
formation of the akyll-enzyme complex by nucelophilic attack at one of two positions in the epoxide,
and activation of water by a His-Acid pair and subsequent hydrolysis of the diol product. By mutating the
residues that are thought to be involved in EH catalysis, theoretically it would be possible to probe the
catalytic mechanism of EH catalysis and allow for further mechanistic and modelling studies. It has been
found in the past that mammalian soluble EHs accumulate up to >60% of the alkyl-enzyme intermediate
when subjected to crystal soak-ins 38,39. While the rate of nucleophilic attack is significantly higher than
the rate of hydrolysis for mammalian EHs, in some cases the level of intermediate in bacterial EHs can
accumulate as little as <1% 40. As such, mutations which selectively impede or impair the hydrolysis step
of EH catalysis should greatly increase the accumulation of the alkyl-enzyme intermediate.
The first site that was selected for mutation was the catalytic triad histidine (H364 in SghF and
H363 in CynF). By mutating this histidine, it is proposed that the enzyme would be unable to hydrolyze
the diol product, leading to an accumulation in the alkyl-enzyme adduct (Figure 13 (A) and Figure A13
(A) in the appendix) . By mutating this amino acid to glutamine, it was thought that not only would the
relatively isosteric mutation be tolerated structurally, but also the loss of the imidazole ring would
disable the enzyme’s ability to relay charge and activate the water molecule that is required for
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hydrolysis. An alanine mutant was also made at this position, due to its non-bulky, chemically inert
methyl functional group. It was also expected that this mutant would be unable to activate the water
molecule that is required for hydrolysis (Figure 13 (B)).

A

B

Figure 15. Proposed mechanism for styrene oxide hydrolysis by (A) SghF-H364Q and (B) SghF-H364A.
In addition, the aspartate responsible for the initial nucelophilic attack in the first step of EH
hydrolysis was targeted for mutagenesis. By mutating this residue, the mutants should lose their ability
to perform a nucleophilic attack on the epoxide carbon, which may lead to an accumulation of the
substrate-bound form of the enzyme (Figure 14 and Figure A15 in the appendix). The isosteric muation
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of this aspartate to asparagine should yield an epoxide hydrolase with a charge at that positon that
opposes the original charge of the aspartate residue.

Figure 16. Proposed mechanism of styrene oxide binding by SghF-D176N
Interestingly, although no activity was found for the mutants CynF-H363A, CynF-H363Q, CynFD176N, SghF-H364A, or SghF-H364Q, SghF-D176N was found to have some activity towards both
enantiomers of styrene oxide (Table 4). There are currently three hypotheses which may explain this
unexpected activity. The first possibility is that a lone pair of electrons from the amine nitrogen allows
for the activation of the neighbouring oxygen, resulting in a nucleophilic attack and an alkyl-enzyme
intermediate closely resembling the intermediate in the native enzyme’s natural catalytic cycle (Figure
15). The enzyme is then able to hydrolyze the alkyl enzyme, similar to the natural catalytic cycle,
resulting in a product diol.
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Figure 17. First hypothesis for observed hydrolase activity in SghF-D176N.
The second hypothesis for the observed SghF-D176N activity is the direct nucleophilic
attack by a lone pair from the amine nitrogen of the aspargine residue. Once again, an alkyl-enzyme
intermediate that closely resembles the native intermediate is formed, and hydrolyzed, resulting in a
product amine. Interestingly, while sodium periodate selectively oxidizes vicinal diols, it has been shown
that it is capable of oxidizing amines to some extent 41. While the identity of the oxidized amine product
is unknown, it still may absorb somewhat at 290nm, resulting in the detection of apparent activity for
SghF-D176N.
While a viable hypothesis, this mechanism can be eliminated. If this mechanism were correct,
then after the first catalytic cycle, the asparagine residue would be reverted back to its native aspartate
(Figure 16). Accompanying this would be an observed increase in the catalytic rate that would be
comparable to the native SghF. However, no increase in apparent activity could be observed for SghFD176N over the time frame of the kinetics reaction. This suggests that this mechanism is not indicative
of the apparent activity of SghF-D176N.
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Figure 18. Second hypothesis for observed hydrolase activity in SghF-D176N
The final hypothesis involves the direct activation of water by H364. In one step, the product
diol is formed through a general base mechanism (Figure 17).

Figure 19. Third hypothesis for observed activity in SghF-D176N
Interestingly, kinetic characterization of CynF reveals that is able to hydrolyze both the (S)- and
(R)- epoxide, with an apparent Kcat/Km of 0.61±0.16 and 0.11±0.013, respectively. CynF has an increased
catalytic efficiency for the (S)-styrene oxide (E=5.55, in favour of the (S)-epoxide), which agrees with the
hypothesis that the (S)-epoxide is the natural and therefore the favoured substrate for enediyneassociated epoxide hydrolases. Kinetic characterization of SghF reveals that it efficiently hydrolyzes the
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substrate analogue (S)-styrene oxide, with an apparent Km of 0.37 ± 0.036 mM and Kcat of 70.3 ± 1.7 min1

, yielding a Kcat/Km of 190. SghF therefore represents the most efficient of the now 7 characterized

enediyne-related epoxide hydrolase for (S)-styrene oxide hydrolysis13. Interestingly, SghF can also
hydrolyze (R)-styrene oxide, with an apparent Kcat/Km of 0.29±0.045 (Table 4). This reduced catalytic
efficiency for the (R)-epoxide once again coincides with the hypothesis that the (S)-epoxide is the natural
substrate for enediyne-associcated epoxide hydrolases 11. SghF strongly prefers hydrolysis of the (S)epoxide, with an E-value of 655 in favour of the (S)-epoxide. This E-value is the largest by one order of
magnitude for any of the characterized enediyne-associated epoxide hydrolases for either enantiomer
of styrene oxide. Thus, SghF may serve as a sensible starting point for future mechanistic and
biochemical studies in order to produce an efficient biocatalyst for the regioselective production of 1phenyl-1,2-ethanediol from styrene oxide.
The regio- and enantioselectivity of EHs provide an intriguing platform for many high-demand
industries that employ traditional chemical synthesis. For instance, EHs are potentially useful in the
pharmaceutical industry, where many enzymes are already employed as catalysts in the production of
drugs whose value in sales often exceed millions of dollars worldwide annually. For example,
semisynthetic penicillins and substrates for the synthesis of other β-lactams can be synthesized using
the enzyme penicillin acylase42. As a whole, the pharmaceutical industry is experiencing a trend towards
the use of biopharmaceuticals. In 2010, five of the top ten grossing drugs worldwide were drugs that
were produced from biological sources 43. In addition, EHs may also be useful in the medical industry as
a diagnostic test, taking advantage of their regioselectivity and ability to hydrolyze a wide variety of
substrates efficiently. Enzymes are already widely employed in diagnostic testing, the most well-known
being the use of glucose oxidase in urine testing 44.
The work described herein sets the table for future studies involving the probing of the α/βepoxide hydrolase mechanism for styrene oxide. Kinetic and regioselectivity characterization of both
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CynF and SghF has determined that SghF may be a robust starting platform for engineering efforts to
generate enantiomerically pure diols through biocatalysis. SghF represents the most efficient (Kcat/Km of
190 for (S)-styrene oxide) and enantioselective (E=655, in favour of the (S)-epoxide) enediyne-associated
epoxide hydrolase characterized to date. The identification of conserved residues at positions Y138,
L187, A188, D189, P190, E191, H192, A194, F229, Q303, L304, and Q370 may represent critical sites for
investigation of a robust catalytic toolkit for the production of enantiomerically pure diols from a wide
variety of epoxide hydrolases and substrates. Finally, regioselectivity characterization of CynF and SghF
has confirmed that CynF is a retaining epoxide hydrolase, and SghF is an inverting epoxide hydrolase,
thereby expanding the inverting versus retaining paradigm for enediyne epoxide hydrolases.
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Appendix 1. Additional Figures
A

B

Figure A1. Preparation of SghF H364Q by overlap extension PCR. (A) PCR amplification of the portion of
the gene upstream of the mutation, (B) PCR amplification of the portion of the gene downstream of the
mutation. Homologous amplicons were pooled together and excised from the gel to increase DNA yield.
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B

A

Figure A2. Preparation of SghF-H364A by overlap extension PCR. (A) PCR amplification of the portion of
the gene upstream of the mutation, (B) PCR amplification of the portion of the gene downstream of the
mutation. Homologous amplicons were pooled together and excised from the gel to increase DNA yield.

A

B

Figure A3. Preparation of CynF-D176N by overlap extension PCR. (A) PCR amplification of the portion of
the gene upstream of the mutation, (B) PCR amplification of the portion of the gene downstream of the
mutation. Homologous amplicons were pooled together and excised from the gel to increase DNA yield.
A

B
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Figure A4. Preparation of CynF-H363Q by overlap extension PCR. (A) PCR amplification of the portion of
the gene upstream of the mutation, (B) PCR amplification of the portion of the gene downstream of the
mutation. Homologous amplicons were pooled together and excised from the gel to increase DNA yield.

B
A

Figure A5. Preparation of CynF-H363A by overlap extension PCR. (A) PCR amplification of the portion of
the gene upstream of the mutation, (B) PCR amplification of the portion of the gene downstream of the
mutation. Homologous amplicons were pooled together and excised from the gel to increase DNA yield.
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Figure A7. Kinetic analysis of SghF-catalyzed hydrolysis of (A) (S)-styrene oxide and (B) (R)-styrene oxide.
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Figure A8. Kinetic analysis of CynF-catalyzed hydrolysis of (A) (S)-styrene oxide and (B) (R)-styrene oxide.
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Figure A8. Kinetic analysis of SghF-D176N-catalyzed hydrolysis of (A) (S)-styrene oxide and (B) (R)styrene oxide.
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Figure A9. Overproduction and purification of (1) CynF-H363A, (2) SghF-D176N, (3) CynF-D175N, and (4)
CynF to near homogeneity as judged by 12% SDS-PAGE.

Figure A10. Overproduction and purification of (1) CynF-H363Q to near homogeneity as judged by 12%
SDS-PAGE.
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Figure A11. Overproduction and purification of (1) SghF-H364Q to near homogeneity as judged by 12%
SDS-PAGE.

Figure A12. Overproduction and purification of (1) SghF-H364A to near homogeneity as judged by 12%
SDS-PAGE.
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Figure A13. Overproduction and purification of (1) SghF to near homogeneity as judged by 12% SDSPAGE.

Scheme A1. Kinetics reaction for monitoring the hydrolysis of styrene oxide by an epoxide hydrolase.
Formation of benzaldehyde is monitored spectrophotometrically at 290nm.
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A

B

Figure A15. Proposed catalytic mechanism for hydrolysis of styrene oxide by (A) CynF-H363Q and (B)
CynF-H363A.

Figure A16. Propopsed mechanism for hydrolysis of styrene oxide by CynF-D175N
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Table A1. Sequences used for EH bioinformatics analysis. Residue refers to the amino acid in position
236 (SghF numbering).
Residue
W
W
W
W
W
W

Y
Y
Y
Y
Y
Y

UniProt
A4X8F5
W2F1W8
B1VRN6

Strain
Salinispora tropica CNB-440
Microbispora sp. ATCC PTA-5024
Streptomyces griseus subsp. Griseus (strain JCM 4626
/ NBRC 13350)
Q8GMH6 Streptomyces globisporus
D6AAC9 Streptomyces ghanaensis ATCC 14672
M0B613 Natrialba asiatica (strain ATCC 700177/
DSM 12278/ JCM9576/ FERM P-10747/ NBRC 102637/
172P1)
L7EXA6
Streptomyces turgidiscabies Car8
D3Q9C0 Stackebrandtia nassauensis (strain DSM 44728/
NRRL B-16338/ NBRC 102104/ LLR-40K-21)
F3M694 Paenibacillus sp. HGF5
F4F709
Verrucosispora maris (strain AB-18-032)
D7BXM8 Streptomyces bingchenggensis (strain BCW-1)
S4Y0k5
Sorangium cellulosum So0157-2

Domain
Bacteria
Bacteria
Bacteria
Bacteria
Bacteria
Archaea

Bacteria
Bacteria
Bacteria
Bacteria
Bacteria
Bacteria

